AbbVie to Move Lutikizumab Into Phase 3 in Hidradenitis Suppurativa
08 Janeiro 2024 - 11:16AM
Dow Jones News
By Colin Kellaher
AbbVie plans to advance its lutikizumab drug candidate into
Phase 3 studies in the inflammatory skin disease hidradenitis
suppurativa following a successful Phase 2 trial.
AbbVie on Monday said adults who had previously failed anti-TNF
therapy and received lutikizumab in the Phase 2 study showed higher
response rates in key primary and secondary endpoint measures of
the disease than those treated with placebo.
The North Chicago, Ill., biopharmaceutical company said there is
a significant unmet medical need in hidradenitis suppurativa, a
chronic and often debilitating disease that can result in lumps,
abscesses and scars under the arms, in the groin and in other areas
of the body.
AbbVie is studying lutikizumab in several immune-mediated
diseases, including hidradenitis suppurativa and ulcerative
colitis. The company last year launched a Phase 3 study of its
blockbuster immunology drug Rinvoq in hidradenitis suppurativa.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 08, 2024 09:01 ET (14:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024